Get the Stockscreener App
2.21
0.45%
-0.01
Pre-market:
2.28
0.07
+3.17%
Acumen Pharmaceuticals Inc stock is traded at $2.21, with a volume of 239.03K.
It is down -0.45% in the last 24 hours and up +29.24% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.22
Open:
$2.22
24h Volume:
239.03K
Relative Volume:
0.73
Market Cap:
$133.87M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.9732
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+0.00%
1M Performance:
+29.24%
6M Performance:
+95.58%
1Y Performance:
-23.26%
1-Day Range:
$2.147
$2.30
1-Week Range:
$2.12
$2.46
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.21 | 134.47M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Will Acumen Pharmaceuticals Inc. stock go up soonTrend Reversal & Entry and Exit Point Strategies - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockMarket Activity Recap & Weekly Sector Rotation Insights - newser.com
Applying chart zones and confluence areas to Acumen Pharmaceuticals Inc.July 2025 Review & Consistent Income Trade Ideas - newser.com
When is the best time to exit Acumen Pharmaceuticals Inc.Market Growth Summary & Real-Time Volume Analysis - newser.com
How to forecast Acumen Pharmaceuticals Inc. trends using time seriesMarket Volume Report & Weekly Chart Analysis and Trade Guides - newser.com
How Acumen Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
Will a bounce in Acumen Pharmaceuticals Inc. offer an exitPortfolio Value Summary & Weekly Chart Analysis and Trade Guides - newser.com
Acumen Pharmaceuticals Inc Stock Analysis and ForecastMarket Volatility Update & Free Stock Predictions and Analysis - earlytimes.in
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Uncovering Opportunities: Beauty Health Among 3 Promising Penny Stocks - simplywall.st
Tools to monitor Acumen Pharmaceuticals Inc. recovery probability2025 AllTime Highs & Growth Focused Entry Reports - newser.com
Published on: 2025-10-29 03:28:22 - newser.com
Published on: 2025-10-29 02:17:26 - newser.com
Is Acumen Pharmaceuticals Inc. stock a buy in volatile markets2025 Trade Ideas & AI Forecasted Entry and Exit Points - fcp.pa.gov.br
Short Squeeze: Will Acumen Pharmaceuticals Inc. stock benefit from infrastructure spendingJuly 2025 Pullbacks & Free Expert Approved Momentum Trade Ideas - Fundação Cultural do Pará
Acumen Pharmaceuticals Inc. stock chart pattern explained2025 Market Trends & Verified Entry Point Detection - newser.com
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):